Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Olle Melander

Principal investigator

Default user image.

Fasting levels of growth hormone are associated with carotid intima media thickness but are not affected by fluvastatin treatment

Author

  • Erik Hallengren
  • Peter Almgren
  • Maria Rosvall
  • Gerd Östling
  • Margaretha Persson
  • Andreas Bergmann
  • Joachim Struck
  • Gunnar Engström
  • Bo Hedblad
  • Olle Melander

Summary, in English

Background: Growth hormone (GH) has been linked to cardiovascular disease but the exact mechanism of this association is still unclear. We here test if the fasting levels of GH are cross-sectionally associated with carotid intima media thickness (IMT) and whether treatment with fluvastatin affects the fasting level of GH. Methods: We examined the association between GH and IMT in 4425 individuals (aged 46-68 years) included in the baseline examination (1991-1994) of the Malmö Diet and Cancer cardiovascular cohort (MDC-CC). From that cohort we then studied 472 individuals (aged 50-70 years) who also participated (1994-1999) in the β-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS), a randomized, double blind, placebo-controlled, single-center clinical trial. Using multivariate linear regression models we related the change in GH-levels at 12 months compared with baseline to treatment with 40 mg fluvastatin once daily. Results: In MDC-CC fasting values of GH exhibited a positive cross-sectional relation to the IMT at the carotid bulb independent of traditional cardiovascular risk factors (p = 0.002). In a gender-stratified analysis the correlation were significant for males (p = 0.005), but not for females (p = 0.09). Treatment with fluvastatin was associated with a minor reduction in the fasting levels of hs-GH in males (p = 0.05) and a minor rise in the same levels among females (p = 0.05). Conclusions: We here demonstrate that higher fasting levels of GH are associated with thicker IMT in the carotid bulb in males. Treatment with fluvastatin for 12 months only had a minor, and probably not clinically relevant, effect on the fasting levels of hs-GH.

Department/s

  • Cardiovascular Research - Hypertension
  • Department Office of Clinical Sciences, Lund
  • Social Medicine and Health Policy
  • Centre for Economic Demography
  • Cardiovascular Research - Immunity and Atherosclerosis
  • Internal Medicine - Epidemiology
  • Cardiovascular Research - Epidemiology
  • Department of Clinical Sciences, Malmö
  • EXODIAB: Excellence in Diabetes Research in Sweden
  • EpiHealth: Epidemiology for Health

Publishing year

2017-05-16

Language

English

Publication/Series

BMC Cardiovascular Disorders

Volume

17

Issue

1

Document type

Journal article

Publisher

BioMed Central (BMC)

Topic

  • Cardiac and Cardiovascular Systems

Keywords

  • Cardiovascular disease
  • Growth hormone
  • Imt
  • Lipids
  • Statins

Status

Published

Research group

  • Cardiovascular Research - Hypertension
  • Social Medicine and Health Policy
  • Cardiovascular Research - Immunity and Atherosclerosis
  • Internal Medicine - Epidemiology
  • Cardiovascular Research - Epidemiology

ISBN/ISSN/Other

  • ISSN: 1471-2261